Khondrion shares progress of sonlicromanol development programme at Mitochondrial Medicine 2020 virtual conference

Print Friendly, PDF & Email

NIJMEGEN, the Netherlands – Monday, November 30, 2020: Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the Company will provide a development overview of its Phase 2B clinical-stage drug sonlicromanol in a poster lightning talk session at the Mitochondrial Medicine 2020 virtual […]